AAAAAA
Results:
1-9
|
Results: 9
Authors:
Piccirillo, JF
Mager, DE
Frisse, ME
Brophy, RH
Goggin, A
Citation: Jf. Piccirillo et al., Impact of first-line vs second-line antibiotics for the treatment of acuteuncomplicated sinusitis, J AM MED A, 286(15), 2001, pp. 1849-1856
Authors:
Mager, DE
Jusko, WJ
Citation: De. Mager et Wj. Jusko, Pharmacodynamic modeling of time-dependent transduction systems, CLIN PHARM, 70(3), 2001, pp. 210-216
Authors:
Naughton, CK
Miller, DC
Mager, DE
Ornstein, DK
Catalona, WJ
Citation: Ck. Naughton et al., A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: Impact on cancer detection, J UROL, 164(2), 2000, pp. 388-392
Authors:
Ramos, CG
Carvahal, GF
Mager, DE
Haberer, B
Catalona, WJ
Citation: Cg. Ramos et al., The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels, J UROL, 162(5), 1999, pp. 1587-1590
Authors:
Catalona, WJ
Carvalhal, GF
Mager, DE
Smith, DS
Citation: Wj. Catalona et al., Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies, J UROL, 162(2), 1999, pp. 433-438
Authors:
Carvalhal, GF
Smith, DS
Ramos, C
Krygiel, J
Mager, DE
Yan, Y
Catalona, WJ
Citation: Gf. Carvalhal et al., Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screening, J UROL, 162(1), 1999, pp. 113-118
Authors:
Ramos, CG
Carvalhal, GF
Smith, DS
Mager, DE
Catalona, WJ
Citation: Cg. Ramos et al., Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer, J UROL, 161(5), 1999, pp. 1525-1529
Authors:
Ramos, CG
Carvalhal, GF
Smith, DS
Mager, DE
Catalona, WJ
Citation: Cg. Ramos et al., Retrospective comparison of radical retropubic prostatectomy and (125)iodine brachytherapy for localized prostate cancer, J UROL, 161(4), 1999, pp. 1212-1215
Authors:
Carvalhal, GF
Smith, DS
Mager, DE
Ramos, C
Catalona, WJ
Citation: Gf. Carvalhal et al., Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less, J UROL, 161(3), 1999, pp. 835-839
Risultati:
1-9
|